Report: Pfizer bids on Sobi; Bellicum buys into TCR;

@FierceBiotech: ICYMI yesterday: Kythera bags FDA approval for its double-chin-shrinking shot. Report | Follow @FierceBiotech

@JohnCFierce: To restate: T-Vec panel demonstrates just how accepting the FDA and its panels are when it comes to "meh" cancer drugs. (Once owned a VTec) | Follow @JohnCFierce

@DamianFierce: Wasn't it odd that $SNTA said Whitaker's new job "allows her to be located closer to her family" in its PR? | Follow @DamianFierce

> Pfizer ($PFE) is the mystery bidder described in Sobi's terse disclosure earlier this week, according to Reuters, eyeing the Swedish drugmaker for a deal that would likely exceed $5 billion. News

> CAR-T player Bellicum Pharmaceuticals ($BLCM) has licensed some TCR technology from the Netherlands' Leiden University Medical Center, investing in a complementary immuno-oncology platform. More

> Chinese CRO WuXi PharmaTech ($WX) is considering going private, entertaining a buyout offer from its CEO and investor Ally Bridge Group. Item

Medical Device News

@FierceMedDev: ICYMI: Kleiner Perkins backs Rapid Micro Biosystems in $25M for microbial detection in quality control. Report | Follow @FierceMedDev

@VarunSaxena2: Drug testing company Cordant raises $12.8M as it seeks to be fragmented industry's one-stop shop. FierceDiagnostics story | Follow @VarunSaxena2

@EmilyWFierce: Researchers Yale used gene editing tech to fix a mutation commonly linked to cystic fibrosis. FierceBiotechResearch article | Follow @EmilyWFierce

> Boston Sci courts hospitals with a pair of deals to boost patient outcomes and lower costs. Story

> Harvard point-of-care handheld cancer diagnostic spinoff WaveGuide raises $13.9M. Report

Pharma News

@FiercePharma: IDEXX misses earnings target, dampens 2015 forecast. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: GSK licks Nicorette manufacturing problems; 'Minis' are back. FiercePharmaManufacturing report | Follow @EricPFierce

@CarlyHFierce: After topping Q1 estimates, Valeant hikes guidance on Salix buy. ICYMI yesterday | Follow @CarlyHFierce

> Novo's purported CEO-to-be is out the door amid executive reshuffle. More

> Lantus dragged down diabetes, but Sanofi beat on sales, earnings anyway. Article

CRO News

> WuXi's CEO moves to take the CRO private. News

> Icon dampens its outlook despite a strong quarter. Report

> Quintiles scales back its 2015 projections after a mixed quarter. More

> Charles River ticks up its revenue amid a shift in focus. Story

> INC swings to profit and dials up its revenue expectations. Article

Vaccines News

> As California measles cases mounted, so did Merck measles vaccine sales. Item

> 80% leap for Pfizer's U.S. Prevnar sales trounces Q1 estimates. Report

> GSK's shingles candidate more effective than Merck's Zostavax in older adults, study says. Story

> Amgen wins FDA panel nod for T-Vec in melanoma. News

> Final trial results show GSK malaria vaccine's efficacy wanes over time. Article

Pharma Manufacturing News

> FDA wants manufacturers to test APIs in hospital antiseptics. More

> AmerisourceBergen keeps up momentum gained from Walgreens deal. News

> Drug shortages become issue in Teva and Mylan hook-up. Article

> Attix Pharmaceuticals recalls hundreds of APIs from the U.S. News

> Hospira's Rocky Mount warning letter lifted; Pfizer benefits. Story

Pharma Asia News

> India works with Hilleman to help industry avoid waste in vaccines stockpile. Report

> China on standardized quality push for traditional medicines. Story

> Singapore's Temasek piles into Indian pharma to the tune of $567.7M. More

> China devices market set to soar by 2020 as GDP overtakes U.S., report says. Item

> Hospital drug sales noted by Premier Li in China reform push. Article

Suggested Articles

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.

The takeover will give Orgenesis control of an autologous cell therapy treatment for respiratory disease caused by COVID-19.